Αρχική World News EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin World News EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin Από Ogkologos - 18 Αυγούστου, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Utility of Genomic Profiling Use for Targeted Therapy in a Phase... 6 Μαΐου, 2025 Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... 6 Δεκεμβρίου, 2019 The Healing Power of Being Outdoors for People With Cancer 23 Ιουλίου, 2020 High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... 17 Μαρτίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... Hairstylist Creates Custom Wigs & Donates Them To Cancer Patients FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally...